Prostate Cancer
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium
January 31, 2024
Current practice and unmet training needs in robotic-assisted radical prostatectomy: investigation from the Junior ERUS/YAU working group.
January 31, 2024
Nonsurgical Interventions to Prevent Disease Progression in Prostate Cancer Patients on Active Surveillance: A Systematic Review and Meta-analysis.
January 31, 2024
Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate Cancer.
January 31, 2024
Updates on Management of Biochemical Recurrent Prostate Cancer.
January 31, 2024
Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations.
January 30, 2024
PARP Inhibitors in Metastatic Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis of Existing Evidence.
January 30, 2024
Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter Study.
January 30, 2024
Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway.
January 29, 2024
The Added Value of Side-specific Systematic Biopsy in Patients Diagnosed by Magnetic Resonance Imaging-targeted Prostate Biopsy.
January 29, 2024
Amount of Gleason Pattern 3 Is Not Predictive of Risk in Grade Group 2-4 Prostate Cancer.
January 29, 2024
Moderate hypofractionated radiotherapy for prostate cancer: 3-year toxicity results of a multicentre randomized phase 3, non-inferiority trial.
January 29, 2024